Skip to main content
. 2017 Nov 2;12(11):e0187304. doi: 10.1371/journal.pone.0187304

Fig 2. Effect of anti-VEGF therapy on protein levels.

Fig 2

Samples were divided in three groups: CON, non-diabetic control patients; PDR—B, PDR patients that did not receive bevacizumab; PDR + B, PDR patients that received bevacizumab. Differences between groups were analyzed with an unpaired t test with Welch's correction. Lines represent mean values.